Favorable prognostic impact of RAS mutation status in multiple myeloma treated with high-dose melphalan and autologous stem cell support in the era of novel agents: a single center perspective

被引：6
作者：
Gebauer, Niklas [1 ]
Biersack, Harald [1 ]
Czerwinska, Ann-Cathrin [2 ]
Schemme, Janina [2 ]
Hardel, Tim Tristan [1 ]
Bernard, Veronica [2 ]
Rades, Dirk [3 ]
Lehnert, Hendrik [1 ]
Luley, Kim Barbara [1 ]
Thorns, Christoph [2 ]
机构：
[1] Univ Hosp Schleswig Holstein, Dept Internal Med 1, Lubeck, Germany
[2] Univ Hosp Schleswig Holstein, Dept Pathol, Reference Ctr Lymph Node Pathol & Hematopathol, Lubeck, Germany
[3] Univ Hosp Schleswig Holstein, Dept Radiat Oncol, Lubeck, Germany
来源：
LEUKEMIA & LYMPHOMA | 2016年 / 57卷 / 01期
关键词：
BORTEZOMIB THERAPY; DEXAMETHASONE;
D O I：
10.3109/10428194.2015.1046863
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：226 / 229
页数：4
相关论文
共 12 条
  • [1] CyBorD induction therapy in clinical practice
    Areethamsirikul, N.
    Masih-Khan, E.
    Chu, C-M
    Jimenez-Zepeda, V.
    Reece, D. E.
    Trudel, S.
    Kukreti, V.
    Tiedemann, R.
    Chen, C.
    [J]. BONE MARROW TRANSPLANTATION, 2015, 50 (03) : 375 - 379
  • [2] Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma
    Benboubker, Lotfi
    Dimopoulos, Meletios A.
    Dispenzieri, Angela
    Catalano, John
    Belch, Andrew R.
    Cavo, Michele
    Pinto, Antonello
    Weisel, Katja
    Ludwig, Heinz
    Bahlis, Nizar
    Banos, Anne
    Tiab, Mourad
    Delforge, Michel
    Cavenagh, Jamie
    Geraldes, Catarina
    Lee, Je-Jung
    Chen, Christine
    Oriol, Albert
    de la Rubia, Javier
    Qiu, Lugui
    White, Darrell J.
    Binder, Daniel
    Anderson, Kenneth
    Fermand, Jean-Paul
    Moreau, Philippe
    Attal, Michel
    Knight, Robert
    Chen, Guang
    Van Oostendorp, Jason
    Jacques, Christian
    Ervin-Haynes, Annette
    Avet-Loiseau, Herve
    Hulin, Cyrille
    Facon, Thierry
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (10) : 906 - 917
  • [3] Clinical and biological significance of RAS mutations in multiple myeloma
    Chng, W. J.
    Gonzalez-Paz, N.
    Price-Troska, T.
    Jacobus, S.
    Rajkumar, S. V.
    Oken, M. M.
    Kyle, R. A.
    Henderson, K. J.
    Van Wier, S.
    Greipp, P.
    Van Ness, B.
    Fonseca, R.
    [J]. LEUKEMIA, 2008, 22 (12) : 2280 - 2284
  • [4] International uniform response criteria for multiple myeloma
    Durie, B. G. M.
    Harousseau, J-L
    Miguel, J. S.
    Blade, J.
    Barlogie, B.
    Anderson, K.
    Gertz, M.
    Dimopoulos, M.
    Westin, J.
    Sonneveld, P.
    Ludwig, H.
    Gahrton, G.
    Beksac, M.
    Crowley, J.
    Belch, A.
    Boccadaro, M.
    Turesson, I.
    Joshua, D.
    Vesole, D.
    Kyle, R.
    Alexanian, R.
    Tricot, G.
    Attal, M.
    Merlini, G.
    Powles, R.
    Richardson, P.
    Shimizu, K.
    Tosi, P.
    Morgan, G.
    Rajkumar, S. V.
    [J]. LEUKEMIA, 2006, 20 (09) : 1467 - 1473
  • [5] Oncogenic RAS mutations in myeloma cells selectively induce cox-2 expression, which participates in enhanced adhesion to fibronectin and chemoresistance
    Hoang, Bao
    Zhu, Li
    Shi, Yijiang
    Frost, Patrick
    Yan, Huajun
    Sharma, Sanjai
    Sharma, Sherven
    Goodglick, Lee
    Dubinett, Steven
    Lichtenstein, Alan
    [J]. BLOOD, 2006, 107 (11) : 4484 - 4490
  • [6] Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy
    Mulligan, George
    Lichter, David I.
    Di Bacco, Alessandra
    Blakemore, Stephen J.
    Berger, Allison
    Koenig, Erik
    Bernard, Hugues
    Trepicchio, William
    Li, Bin
    Neuwirth, Rachel
    Chattopadhyay, Nibedita
    Bolen, Joseph B.
    Dorner, Andrew J.
    van de Velde, Helgi
    Ricci, Deborah
    Jagannath, Sundar
    Berenson, James R.
    Richardson, Paul G.
    Stadtmauer, Edward A.
    Orlowski, Robert Z.
    Lonial, Sagar
    Anderson, Kenneth C.
    Sonneveld, Pieter
    San Miguel, Jesus F.
    Esseltine, Dixie-Lee
    Schu, Matthew
    [J]. BLOOD, 2014, 123 (05) : 632 - 639
  • [7] Palumbo A, 2013, ASH ANN M 2013 NEW O
  • [8] Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study
    Rosinol, Laura
    Oriol, Albert
    Isabel Teruel, Ana
    Hernandez, Dolores
    Lopez-Jimenez, Javier
    de la Rubia, Javier
    Granell, Miquel
    Besalduch, Joan
    Palomera, Luis
    Gonzalez, Yolanda
    Asuncion Etxebeste, Ma
    Diaz-Mediavilla, Joaquin
    Hernandez, Miguel T.
    de Arriba, Felipe
    Gutierrez, Norma C.
    Luisa Martin-Ramos, Ma
    Teresa Cibeira, Ma
    Victoria Mateos, Ma
    Martinez, Joaquin
    Alegre, Adrian
    Jose Lahuerta, Juan
    San Miguel, Jesus
    Blade, Joan
    [J]. BLOOD, 2012, 120 (08) : 1589 - 1596
  • [9] Targeting RAS-ERK signalling in cancer: promises and challenges
    Samatar, Ahmed A.
    Poulikakos, Poulikos I.
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2014, 13 (12) : 928 - +
  • [10] RAS mutation status and bortezomib therapy for relapsed multiple myeloma
    Smith, Dean
    Armenteros, Elena
    Percy, Laura
    Kumar, Madhu
    Lach, Anna
    Herledan, Gaelle
    Stubbs, Matthew
    Downward, Julian
    Yong, Kwee
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2015, 169 (06) : 905 - 908
12